Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Tribe Technology (TRYB) by Steve Moore in ShareProphets
- Sell Seeing Machines Ltd. NPV (DI) (SEE) by Steve Moore in ShareProphets
- Sell Quiz (QUIZ) by Steve Moore in ShareProphets
- Buy Croda International (CRDA) by Tom Winnifrith in ShareProphets
- Buy British American Tobacco (BATS) by Mark David Hartley in The Motley Fool
- Buy Diageo (DGE) by Stephen Wright in The Motley Fool
- Buy Taylor Wimpey (TW.) by Harvey Jones in The Motley Fool
- Avoid Inspects Group (SPEC) by Steve Moore in ShareProphets
- Buy Zotefoams (ZTF) by Hot Stock Rockets in ShareProphets
- Neutral Ceres Power Holdings (CWR) by Goldman Sachs
- Sell Bunzl (BNZL) by Goldman Sachs
- Buy Anglo American (AAL) by Stephen Wright in The Motley Fool
- Hold AstraZeneca (AZN) by Ben McPoland in The Motley Fool
- Hold BAE Systems (BA.) by Ben McPoland in The Motley Fool
- Buy Land Securities Group (LAND) by Robert Stephens (Telegraph) in The Telegraph - Questor
- Buy Greggs (GRG) by Ben McPoland in The Motley Fool
- Sell Inspired (INSE) by Steve Moore in ShareProphets
- Neutral Schroders (SDR) by JP Morgan
- Sell Jaywing (JWNG) by Steve Moore in ShareProphets
- Sell Jubilee Metals Group (JLP) by Tom Winnifrith in ShareProphets
Avacta Group (AVCT) Share Price
Health Care Sector
NOTE: This is based on 60 open tips for Avacta Group (AVCT)
| Latest Bid : 48.00p | Latest Ask : 51.00p |
| High Today : 51.00p | Low Today : 47.46p |
| This Years High : 117.00p | This Years Low : 39.75p |
| Volume : 1,678,933 | MKT Cap : £182.66M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Stock Splits and Consolidations
26/01/2016 – Stock Consolidation 100.000:1.000
Avacta Group (AVCT) Overview
Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative, proprietary Affimer® and pre|CISION platforms.Avacta Group (AVCT) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-12-12 13:30:00 12/12/2024 | -15.12% |
| Hold | Deutsche Bank | Premium Only | 2024-12-10 07:30:00 10/12/2024 | 9.39% |
| Sell | Tom Winnifrith | Premium Only | 2024-09-17 10:35:00 17/09/2024 | 13.16% |
| Sell | Deutsche Bank | Premium Only | 2024-09-17 07:27:00 17/09/2024 | 33.46% |
| Sell | Tom Winnifrith | Premium Only | 2024-06-26 09:30:00 26/06/2024 | -10.00% |
Avacta Group (AVCT) Active Short Positions
| Fund Manager | Position | Date |
|---|---|---|
| GSA Capital Partners LLP | 0.78% | 10/07/2024 |
| Latest Bid : 48.00p | Latest Ask : 51.00p |
| High Today : 51.00p | Low Today : 47.46p |
| This Years High : 117.00p | This Years Low : 39.75p |
| Volume : 1,678,933 | MKT Cap : £182.66M |
Avacta Group Overview
Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative, proprietary Affimer® and pre|CISION platforms.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Avacta Group Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-12-12 13:30:00 12/12/2024 | -15.12% |
| Hold | Deutsche Bank | Premium Only | 2024-12-10 07:30:00 10/12/2024 | 9.39% |
| Sell | Tom Winnifrith | Premium Only | 2024-09-17 10:35:00 17/09/2024 | 13.16% |
| Sell | Deutsche Bank | Premium Only | 2024-09-17 07:27:00 17/09/2024 | 33.46% |
| Sell | Tom Winnifrith | Premium Only | 2024-06-26 09:30:00 26/06/2024 | -10.00% |
Stock Splits and Consolidations
26/01/2016 – Stock Consolidation 100.000:1.000